Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

SRR35579841

· B

a42a77da-f120-5217-b9ee-24490d8bd08f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
B
subtype
B

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ESTROGEN_RESPONSE_EARLY+0.220
  • INTERFERON_ALPHA_RESPONSE+0.200
  • ALLOGRAFT_REJECTION+0.140
  • KRAS_SIGNALING_DN+0.140
  • DNA_REPAIR+0.130
  • ESTROGEN_RESPONSE_LATE+0.090
  • PEROXISOME+0.070
  • BILE_ACID_METABOLISM+0.060
  • INTERFERON_GAMMA_RESPONSE+0.020
  • WNT_BETA_CATENIN_SIGNALING+0.010

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
  • ANGIOGENESIS-0.490
  • PROTEIN_SECRETION-0.490
  • TGF_BETA_SIGNALING-0.430
  • MTORC1_SIGNALING-0.420
  • ANDROGEN_RESPONSE-0.390
  • HYPOXIA-0.380
  • KRAS_SIGNALING_UP-0.330
  • TNFA_SIGNALING_VIA_NFKB-0.330
  • UV_RESPONSE_DN-0.330

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120050097.LumA
breast-umap@18
B0.881
2SRR33532821
breast-umap@18
D0.864
3TCGA-OL-A5D8-01A-11R-A27Q-07
breast-umap@18
B0.852
4SRR1313108
breast-umap@18
B0.843
5TCGA-EW-A423-01A-11R-A24H-07
breast-umap@18
B0.816
6R87
bladder-landscape@3
0.813
7SJEPD019_D.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.811
8TCGA-MP-A4T6-01A-32R-A262-07
lung-landscapes@6
cohortA10.811
9MBCProject_4647_T0_RNA
breast-umap@18
B0.806
10MNG1106
mng-umap@100
0.803

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 10 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ESTROGEN_RESPONSE_EARLY0.220Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.200Inavolisib— uncovered
ALLOGRAFT_REJECTION0.140Idelalisib— uncovered
KRAS_SIGNALING_DN0.140Remibrutinib— uncovered
DNA_REPAIR0.130Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.090Idelalisib— uncovered
PEROXISOME0.070Idelalisib— uncovered
BILE_ACID_METABOLISM0.060Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.020Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.010Inavolisib— uncovered